Essential Partners’s United Therapeutics UTHR Stock Holding History

Essential Partners’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$109K	Sell	202 -87	-30%	-$45K	0.05%	404
2026 Q2	$157K	Sell	289 -44	-13%	-$24.8K	0.07%	303
2026 Q1	$197K	Sell	333 -1,247	-79%	-$621K	0.07%	296
2025 Q4	$770K	Buy	1,580 +1,388	+723%	+$646K	0.24%	120
2025 Q3	$80.5K	Sell	192 -2	-1%	-$673	0.03%	483
2025 Q2	$55.7K	Buy	+194	New	+$58K	0.02%	450

Other funds holding UTHR

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Polaris Capital Management Boston, Massachusetts $953M AUM 27.74% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

Livforsakringsbolaget Skandia Stockholm, Sweden $3.02B AUM 43.19% 1-Year Est. Return

Nepsis Inc Minneapolis, Minnesota $317M AUM 37.22% 1-Year Est. Return

Essential Partners's UTHR Position: Q3 2026 in Review

Essential Partners reduced its United Therapeutics (UTHR) stake by 30% in Q3 2026, selling an estimated $45K and leaving 202 shares worth $109K. The position accounts for 0.05% of the portfolio, ranked #404.

Essential Partners first reported a position in UTHR in Q2 2025 and has held it in 6 quarters since. The position peaked at $770K in Q4 2025. 145 funds tracked by Wall St. Rank hold UTHR as of Q3 2026.

Essential Partners held 202 shares of United Therapeutics worth $109K as of Q3 2026.
Essential Partners sold 87 United Therapeutics shares in Q3 2026, an estimated $45K.
United Therapeutics made up 0.05% of Essential Partners's portfolio in Q3 2026, its #404 holding.
Essential Partners first reported a position in United Therapeutics in Q2 2025 and has held it in 6 quarters since.
Essential Partners's United Therapeutics position peaked at $770K in Q4 2025.
145 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.